A whitening composition containing PDRN and SOD enzyme

Abstract

This invention discloses a whitening composition containing PDRN and SOD enzymes. The composition includes Selaginella tamariscina extract, mulberry root extract, *Strombus haematocephala* extract, and a nucleotide protein complex, wherein the nucleotide protein complex includes PDRN and SOD enzymes. The composition obtained by scientifically combining Selaginella tamariscina extract, mulberry root extract, *Strombus haematocephala* extract, and the nucleotide protein complex exhibits a significant inhibitory effect on tyrosinase activity and is safe and highly effective, making it widely applicable in the cosmetics field.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, specifically to a whitening composition containing PDRN and SOD enzyme. Background Technology

[0002] In recent years, with the increasing pursuit of skin whitening, the development of highly effective and safe tyrosinase inhibitors has become a research hotspot in the cosmetics field. Tyrosinase, as a key enzyme in melanin synthesis, directly affects the degree of skin pigmentation. However, existing methods for inhibiting tyrosinase have the following limitations:

[0003] Currently, most commercially available skin whitening products rely on a single active ingredient (such as arbutin, kojic acid, and vitamin C derivatives). While these ingredients have some inhibitory effects, they are easily affected by environmental factors (such as ultraviolet radiation and oxidative stress), and long-term use may lead to increased skin tolerance or impaired skin barrier function. For example, arbutin is easily decomposed and inactivated under strong light, while kojic acid may cause skin sensitivity.

[0004] Tyrosinase activity is regulated in multiple dimensions, including gene transcription (e.g., MITF protein), enzyme protein modification (e.g., phosphorylation activation), cofactor binding (e.g., Cu²⁺ chelation), and substrate competition. Existing formulations mostly target single sites (e.g., directly inhibiting enzyme activity or scavenging free radicals), making it difficult to achieve full-cycle regulation, resulting in insufficient inhibition efficiency.

[0005] Although PDRN (polydeoxyribonucleic acid) has been shown to promote cell proliferation and repair by activating A2A adenosine receptors, and SOD (superoxide dismutase) can enhance antioxidant capacity by scavenging superoxide anions, their synergistic application in the field of skin whitening has not yet been reported. When used alone, PDRN has a weak tyrosinase inhibitory effect, while SOD has limited direct inhibitory effect, necessitating the design of complementary combinations to achieve functional complementarity.

[0006] To address the aforementioned issues, there is an urgent need to develop a multi-target synergistic, safe, gentle, and highly stable skin whitening composition. By integrating natural plant extracts, functional nucleic acid components (PDRN), and antioxidant enzymes (SOD), a complex system targeting the entire lifecycle regulation of tyrosinase can be constructed to meet the market's pressing demand for highly effective and low-irritation skin whitening products. Summary of the Invention

[0007] Based on this, the purpose of the present invention is to overcome the shortcomings of the prior art and provide a whitening composition containing PDRN and SOD enzyme.

[0008] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0009] In a first aspect, the present invention provides a skin-whitening composition containing PDRN and SOD enzyme, said composition comprising the following components in parts by weight:

[0010] Selaginella extract: 2-4 parts;

[0011] Mulberry root extract: 1-3 parts;

[0012] Oenanthera extract: 8-10 parts;

[0013] Nucleotide-protein complex: 0.5-1.5 parts;

[0014] The nucleotide-protein complex includes PDRN and SOD enzyme.

[0015] Preferably, the average molecular weight of the PDRN is 50-850 kDa; and the SOD enzyme activity is 50,000-200,000 U / g.

[0016] Preferably, the mass ratio of PDRN to SOD enzyme in the nucleotide protein complex is 1:0.6-1.3.

[0017] Secondly, the present invention provides the application of the whitening composition containing PDRN and SOD enzyme described in the first aspect in the preparation of cosmetics with whitening effects.

[0018] Preferably, the dosage form of the whitening cosmetic includes any one of face cream, lotion, and serum.

[0019] Thirdly, the present invention provides a whitening serum, the serum comprising 0.1-5 wt% of the whitening composition containing PDRN and SOD enzyme described in the first aspect.

[0020] Preferably, the whitening essence further includes moisturizers, preservatives, thickeners, pH adjusters, and deionized water.

[0021] Preferably, the moisturizer is at least one of sodium hyaluronate, glycerin, and squalane.

[0022] Preferably, the preservative is at least one of p-hydroxyacetophenone, ethylhexylglycerin, and octyl glycol.

[0023] Preferably, the thickener is at least one of xanthan gum, hydroxyethyl cellulose, ammonium acryloyldimethyl taurate / VP copolymer, and sodium polyacryloyldimethyl taurate.

[0024] Preferably, the pH adjuster is tromethamine.

[0025] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0026] The whitening composition containing PDRN and SOD enzymes of this invention contains *Hymenochaetus erinaceus* extract, *Selaginella tamariscina* extract, mulberry root extract, and a nucleotide protein complex, wherein the nucleotide protein complex contains PDRN and SOD enzymes. These five components achieve synergistic effects in inhibiting tyrosinase through full-cycle synergistic regulation, effectively inhibiting tyrosinase activity. Specifically, *Hymenochaetus erinaceus* extract targets and inhibits the activation of the key transcription factor MITF of tyrosinase, reducing the total amount of tyrosinase synthesized at the source. *Selaginella tamariscina* extract inhibits the phosphorylation activation of synthesized tyrosinase by blocking downstream signals of MITF, reducing its functional activity. Mulberry root extract is rich in polyphenols, which chelate copper ions of tyrosinase through the catechol structure, depriving tyrosinase of its catalytic center and inactivating it. The enzymatic oligosaccharides in *Hymenochaetus erinaceus* extract and the flavonoids in *Selaginella tamariscina* extract synergistically block the amino acid residue binding sites of tyrosinase, preventing substrate entry and doubly blocking the enzyme's catalytic function. The nucleotide-protein complex (PDRN+SOD) further enhances the effect. PDRN activates the A2A adenosine receptor on melanocytes, promoting the targeted accumulation of other active ingredients in the composition (Selaginella tamariscina extract, Morus alba bark extract, and Ophiopogon japonicus extract) onto melanocytes. SOD catalyzes the conversion of superoxide anions, maintaining microenvironmental stability and preventing the oxidation and destruction of other active substances in the composition, thus ensuring the sustainability of the inhibitory effect. Through a synergistic chain of "reducing synthesis - inhibiting activation - chelating metal ions - blocking sites - enrichment and stabilization," the five components significantly enhance the inhibitory ability against tyrosinase, achieving a significant synergistic effect. Detailed Implementation

[0027] To better illustrate the purpose, technical solution, and advantages of this invention, the invention will be further described below with reference to specific embodiments. The purpose is to provide a detailed understanding of the invention, not to limit it. All other embodiments obtained by those skilled in the art without inventive effort are within the scope of protection of this invention. Unless otherwise specified, the experimental reagents and instruments designed in the embodiments and comparative examples of this invention are commonly used reagents and instruments, all of which are commercially available. Unless otherwise specified, the experimental methods used in the embodiments and comparative examples are conventional methods; and unless otherwise specified, the raw materials used in parallel experiments are from the same batch.

[0028] Further explanation of the raw materials used in this invention:

[0029] The extract of *Strombyx mori* was purchased from CODIF TECHNOLOGIE NATURELLE, catalog number: CYBRIGHT.

[0030] The Selaginella extract was purchased from Shanghai Jiakai Biotechnology Co., Ltd., product code: Gerbex® Selaginella.

[0031] The mulberry root extract was purchased from Yunnan Yingge Biotechnology Co., Ltd., product number: Mobai.

[0032] PDRN was purchased from Baiman Biotechnology (Shanghai) Co., Ltd., catalog number: RJMPDRN-850K, average molecular weight 850 kDa; catalog number: RJMPDRN-C02, average molecular weight: 400 kDa; catalog number: RJMPDRN-S02, average molecular weight: 50 kDa.

[0033] SOD enzymes were purchased from Shenzhen Zhongke Xinyang Biotechnology Co., Ltd., with the following product codes: SYSTASE® O-SOD-200,000 (enzyme activity: 200,000 U / g); SYSTASE® O-SOD-100,000 (enzyme activity: 100,000 U / g); and SYSTASE® O-SOD-50,000 (enzyme activity: 50,000 U / g).

[0034] All other raw materials and reagents are commercially available.

[0035] A skin whitening composition containing PDRN and SOD enzyme, its components, parts by weight, and preparation method are as follows:

[0036] Composition 1:

[0037] Selaginella extract: 3 parts;

[0038] Mulberry root extract: 2 parts;

[0039] Oenanthera extract: 9 parts;

[0040] Nucleotide-protein complex: 1 part;

[0041] The nucleotide-protein complex is composed of PDRN and SOD enzyme, wherein the mass ratio of PDRN to SOD enzyme is 1:0.8, the average molecular weight of PDRN is 50 kDa, and the SOD enzyme activity is 200,000 U / g.

[0042] Preparation method: Mix the Selaginella tamariscina extract, Morus alba root extract, Ophiopogon japonicus extract, and nucleotide protein complex evenly, seal, and store at 5°C away from light.

[0043] Composition 2:

[0044] Selaginella extract: 2 parts;

[0045] Mulberry root extract: 1 part;

[0046] Oenanthera extract: 8 parts;

[0047] Nucleotide-protein complex: 0.5 parts;

[0048] The nucleotide protein complex is composed of PDRN and SOD enzyme, wherein the mass ratio of PDRN to SOD enzyme is 1:0.6, the average molecular weight of PDRN is 400 kDa, and the SOD enzyme activity is 50,000 U / g.

[0049] Preparation method: Mix the Selaginella tamariscina extract, Morus alba root extract, Ophiopogon japonicus extract, and nucleotide protein complex evenly, seal, and store at 5°C away from light.

[0050] Composition 3:

[0051] Selaginella extract: 4 parts;

[0052] Mulberry root extract: 3 parts;

[0053] Oenanthera extract: 10 parts;

[0054] Nucleotide-protein complex: 1.5 parts;

[0055] The nucleotide-protein complex is composed of PDRN and SOD enzyme, wherein the mass ratio of PDRN to SOD enzyme is 1:1.3, the average molecular weight of PDRN is 850 kDa, and the SOD enzyme activity is 100,000 U / g.

[0056] Preparation method: Mix the Selaginella tamariscina extract, Morus alba root extract, Ophiopogon japonicus extract, and nucleotide protein complex evenly, seal, and store at 5°C away from light.

[0057] Composition ①:

[0058] Unlike composition 1, it lacks Selaginella extract. The missing mass fraction is made up by 2:9 ratio of mulberry root extract and galangal extract. The remaining components and their mass fractions are the same as those in composition 1.

[0059] Preparation method: Mix mulberry root extract, euryale extract, and nucleotide protein complex evenly, seal, and store at 5°C away from light.

[0060] Composition ②:

[0061] Unlike composition 1, it lacks mulberry root extract. The missing mass fraction is made up by 3:9 ratio of Selaginella tamariscina extract and Ophiopogon japonicus extract. The remaining components and their mass fractions are the same as those in composition 1.

[0062] Preparation method: Mix the Selaginella tamariscina extract, Oenanthera salsa extract, and nucleotide protein complex evenly, seal, and store at 5°C away from light.

[0063] Composition ③:

[0064] Unlike composition 1, it lacks the extract of *Euphorbia lathyris*. The missing mass fraction is made up by 3:2 of mulberry root extract and *Selaginella tamariscina* extract. The remaining components and their mass fractions are the same as those in composition 1.

[0065] Preparation method: Mix the Selaginella extract, Morus root extract and nucleotide protein complex evenly, seal and store at 5°C away from light.

[0066] Composition ④:

[0067] Unlike composition 1, PDRN with an average molecular weight of 50 kDa is used to replace the nucleotide protein complex by mass, while the remaining components and their mass fractions are the same as those in composition 1.

[0068] Preparation method: Mix the Selaginella tamariscina extract, Morus alba root extract, Ophiopogon japonicus extract and PDRN evenly, seal and store at 5°C away from light.

[0069] Composition ⑤:

[0070] Unlike Composition 1, the nucleotide protein complex is replaced by an SOD enzyme with an enzyme activity of 200,000 U / g, while the remaining components and their mass fractions are the same as those in Composition 1.

[0071] Preparation method: Mix the Selaginella extract, Morus root extract, Ophiopogon japonicus extract and SOD enzyme evenly, seal and store at 5°C away from light.

[0072] Composition ⑥:

[0073] Unlike composition 1, this composition lacks a nucleotide protein complex. The missing mass fraction is made up by extracts of Selaginella tamariscina, Morus alba root, and Ophiopogon japonicus in a mass ratio of 3:2:9. The remaining components and their mass fractions are the same as those in composition 1.

[0074] Preparation method: Mix the Selaginella tamariscina extract, Morus alba root extract and Ophiopogon japonicus extract evenly, seal and store at 5°C away from light.

[0075] Composition ⑦:

[0076] Unlike Composition 1, it lacks Selaginella extract, Morus root extract, and Ophiopogon japonicus extract. The missing mass fractions are made up by a nucleotide protein complex, which is composed of PDRN and SOD enzyme, wherein the mass ratio of PDRN to SOD enzyme is 1:0.8, the average molecular weight of PDRN is 50 kDa, and the SOD enzyme activity is 200,000 U / g. The remaining components and their mass fractions are the same as those in Composition 1.

[0077] Preparation method: Seal the nucleotide protein complex and store it at 5°C in the dark.

[0078] Composition ⑧:

[0079] Selaginella extract: 9 parts;

[0080] Mulberry root extract: 1 part;

[0081] Oenanthera extract: 3 parts;

[0082] Nucleotide-protein complex: 2 parts;

[0083] The nucleotide-protein complex is composed of PDRN and SOD enzyme, wherein the mass ratio of PDRN to SOD enzyme is 1:0.8, the average molecular weight of PDRN is 50 kDa, and the SOD enzyme activity is 200,000 U / g.

[0084] The preparation method is the same as that of composition 1.

[0085] A whitening serum, the components and their mass percentages are shown in Table 1 below:

[0086] Table 1. Components and weight percentage of serums with whitening effects

[0087]

[0088] Note: "-" indicates no addition; "appropriate amount" in pH adjuster means adjust the pH to the specified pH, which is the pH specified in the essence preparation steps.

[0089] The preparation method of the above-mentioned essence 1 is as follows:

[0090] Step 1: Mix the composition, preservative, humectant and 1 / 2 deionized water at 25°C to obtain mixture A;

[0091] Step 2: Mix the thickener with 1 / 4 deionized water at 40°C until homogeneous to obtain mixture B;

[0092] Step 3: After mixture B cools to 25°C, mix mixture B with mixture A and the remaining deionized water evenly and adjust the pH to 6 using a pH adjuster to obtain the essence.

[0093] The preparation methods for serums 1-5 and serums ①-⑧ are the same as those for serum 1.

[0094] The preparation method for blank serum is as follows:

[0095] Step 1: Mix the preservative, humectant and 1 / 2 deionized water at 25°C until homogeneous to obtain mixture A;

[0096] Step 2: Mix the thickener with 1 / 4 deionized water at 40°C until homogeneous to obtain mixture B;

[0097] Step 3: After mixture B cools to 25°C, mix mixture B with mixture A and the remaining deionized water evenly and adjust the pH to 6 using a pH adjuster to obtain the essence.

[0098] Experiment 1: Tyrosinase Inhibition Test

[0099] Tyrosinase activity is related to melanin synthesis; inhibiting tyrosinase activity can reduce melanin production in the skin. This study evaluates the skin-whitening efficacy of the composition by its effect on tyrosinase activity.

[0100] Solvent preparation:

[0101] PBS buffer: purchased from Solarbio; catalog number: P1039;

[0102] L-Tyrosine solution: Dissolve L-tyrosine in PBS buffer to a final concentration of 0.5 mg / mL;

[0103] Tyrosinase solution: Dissolve tyrosinase in PBS buffer to a final concentration of 500 U / mL;

[0104] Sample solutions: Prepare 1wt% sample solutions of compositions 1-3 and compositions ①-⑧ using deionized water.

[0105] Test method:

[0106] In 96-well microplates, samples were added according to the following groups: solvent background group, solvent reaction group and sample background group, and sample reaction group, with three replicates for each group. First, L-tyrosine solution, sample solution / deionized water, and PBS buffer were added to each well sequentially, mixed thoroughly, and incubated at 37°C in the dark for 10 min. Then, 20 μL of tyrosinase solution was added to each well sequentially, and the mixture was incubated at 37°C for 5 min ± 5 s. The absorbance was immediately measured at 475 nm using a microplate reader. The amounts added to each well are shown in Table 2 below.

[0107] Table 2. Dosage per well in tyrosinase inhibition test

[0108] Components Solvent background group (A) Solvent reaction group (B) Sample background group (C) Sample reaction group (D) L-tyrosine solution (μL) 0 40 0 40 Sample solution (μL) 0 0 40 40 Deionized water (μL) 40 40 0 0 PBS buffer (μL) 70 30 70 30 Tyrosinase solution (μL) 20 20 20 20 Total (μL) 130 130 130 130

[0109] The tyrosinase inhibition rate is calculated using the following formula:

[0110] Tyrosinase inhibition rate / % = [1 - (DC) / (BA)] × 100%.

[0111] The results are shown in Table 3.

[0112] Table 3 Inhibition rate of the composition on tyrosinase

[0113] Group Tyrosinase inhibition rate / % Composition 1 65.72 Composition 2 63.62 Composition 3 63.94 Composition ① 42.44 Composition ② 38.31 Composition ③ 47.62 Composition ④ 56.52 Composition ⑤ 54.91 Composition ⑥ 50.37 Composition ⑦ 10.64 Composition ⑧ 57.33

[0114] As shown in Table 3, the compositions of this invention have significant inhibitory effects on tyrosinase. Comparing the results of Composition 1 with those of Compositions ①-③, it is evident that the extracts of *Selaginella tamariscina*, *Morus alba* root, and *Hymenochaenia galbana* exhibit a significant synergistic effect, and their combined use with nucleotide-protein complexes significantly enhances the inhibitory effect of the compositions on tyrosinase. Comparing the results of Composition 1 with those of Compositions ④-⑤, it is evident that the combined use of PDRN and SOD enzymes with *Selaginella tamariscina*, *Morus alba* root, and *Hymenochaenia galbana* extracts significantly enhances the inhibitory effect of the compositions on tyrosinase, indicating a significant synergistic effect between PDRN and SOD enzymes. Comparing the results of Composition 1 with those of Compositions ⑥-⑦, it is evident that the extracts of *Selaginella tamariscina*, *Morus alba* root, and *Hymenochaenia galbana* extracts, along with PDRN and SOD enzymes, significantly enhance the inhibitory effect of the compositions on tyrosinase, indicating a significant synergistic effect between PDRN and SOD enzymes. There is a significant synergistic effect between PDRN and SOD enzymes. Data from composition ⑦ shows that the nucleotide-protein complex composed of PDRN and SOD enzymes itself has poor inhibitory efficacy against tyrosinase. However, when used in combination with Selaginella tamariscina extract, Morus alba root extract, and Ophiopogon japonicus extract, it enhances the tyrosinase inhibitory efficacy of the composition composed of these extracts. This indicates a significant synergistic effect between PDRN, SOD enzymes, and these extracts. Comparing the results of compositions 1-3 with those of composition ⑧, it is clear that the optimal efficacy is achieved within the range defined by this invention, considering the mass fractions of Selaginella tamariscina extract, Morus alba root extract, Ophiopogon japonicus extract, PDRN, and SOD enzymes used in this invention.

[0115] Human efficacy trials:

[0116] Test 2: Safety Test

[0117] Experiment A:

[0118] Human skin patch test

[0119] Test substances: serums 1-5, serums ①-⑧, and blank serum.

[0120] Subject selection: Healthy subjects aged 31-47 years were selected who voluntarily participated and signed an informed consent form, and were able to complete the test as required during the testing period. Subjects were randomly assigned to groups of 30, with each group corresponding to one test substance.

[0121] Experimental method: Select qualified patch equipment, take 1g of the test substance and place it in the patch applicator and spread it evenly. Then, use topical hypoallergenic adhesive tape to apply the patch applicator to the flexor side of the subject's forearm. Remove the test substance after 24 hours. Observe and record the skin reaction at 0.5, 24 and 48 hours after removal.

[0122] Results evaluation: Adverse skin reactions were graded according to the classification of adverse skin reactions in human trials as specified in the "Cosmetic Safety Technical Specifications" (2015 edition). The grading criteria are shown in Table 4 and the results are shown in Table 5.

[0123] Table 4. Grading Criteria for Adverse Skin Reactions

[0124] Classification Phenomenon Level 0 No skin reaction Level 1 Light red spots appeared on the skin Level 2 Skin shows erythema, infiltration and papules Level 3 Skin erythema, edema, papules and vesicles Level 4 Skin erythema, edema and blisters

[0125] Table 5 Results of human skin patch test

[0126]

[0127] Test B: Human suitability test for sensitive skin

[0128] Test substances: serums 1-5, serums ①-⑧, and blank serum.

[0129] Subject selection: Healthy subjects aged 31-47 years who were positive for lactic acid stinging test, voluntarily participated and signed informed consent form, and were able to complete the test as required during the test period were selected. Subjects were randomly assigned to one test substance, with 30 subjects in each group.

[0130] Experimental Methods: Subjects randomly divided their faces into test and control sides. After cleansing, the test product was applied evenly to the skin on the test side according to the instructions. The control side was not treated with the test product. After 28 days of use, subjects reported local skin reactions. If adverse reactions occurred, a dermatologist evaluated the adverse reactions.

[0131] Results evaluation: Adverse skin reactions were graded according to the classification of adverse skin reactions in human trials as specified in the "Cosmetic Safety Technical Specifications" (2015 edition). The grading criteria are shown in Table 4 and the results are shown in Table 6.

[0132] Table 6 Results of Human Trial

[0133]

[0134] Based on the results of human skin patch tests, serums 1-5 and 1-8 showed good safety during the testing period, and no adverse reactions were observed in the subjects.

[0135] Based on the results of the sensitivity skin suitability test, no adverse skin reactions were observed in any of the subjects during the test period, indicating that serums 1-5 and 1-8 are safe, gentle and non-irritating, and suitable for people with sensitive skin.

[0136] Experiment 3: Whitening Efficacy Test

[0137] Based on the results in Table 3 above, the present invention further tested the whitening efficacy of the serum containing the whitening composition of PDRN and SOD enzyme, and the results are shown in Table 7.

[0138] Test samples: serums 1-5, serums ①-⑧, blank serum.

[0139] Subjects: Healthy subjects aged 31-47 years were selected, with one test sample per group and 30 subjects per group.

[0140] Test sample usage instructions: Use the test sample once in the morning and once in the evening, 0.5 mL each time; apply to the face.

[0141] Test Method: The DermaLab Combo skin analyzer was used to measure the ITA value of the test area on the subject's skin before application. This value was recorded as the ITA value before application, and the measurement area was marked. The subject then received the test sample and applied it as instructed, ensuring complete coverage of the measurement area. The day after the test, the subject returned to the testing site, and the ITA value of the measurement area was measured again, recorded as the ITA value after 56 days of application. The rate of change in ITA value was calculated using a formula. A higher rate of change in ITA value indicates less melanin in the skin, resulting in a whiter appearance.

[0142] ITA value change rate / % = (ITA value after 56 days of use - ITA value before use) / ITA value before use × 100%.

[0143] Table 7 Effects of the Composition on Skin Whitening

[0144] Test sample Number of subjects ITA value before use ITA value after 56 days of use ITA value change rate / % Serum 1 30 24.64 33.38 35.47 Serum 2 30 25.12 29.36 16.88 Serum 3 30 24.84 34.27 37.96 Serum 4 30 24.49 32.71 33.56 Serum 5 30 25.94 34.29 32.19 Serum ① 30 25.53 31.25 22.41 Serum ② 30 25.01 29.93 19.67 Serum ③ 30 24.85 31.27 25.84 Essence ④ 30 24.63 31.86 29.35 Essence ⑤ 30 24.23 30.91 27.57 Essence ⑥ 30 25.26 32.21 27.51 Essence ⑦ 30 25.69 28.06 9.23 Serum ⑧ 30 24.11 31.42 30.32 Blank Essence 30 24.50 25.14 2.61

[0145] As shown in Table 7, serums 1-5 and serums ①-⑧ all have certain whitening effects. A comparison of serums 1-3 and the blank serum shows that the whitening composition containing PDRN and SOD enzymes has certain whitening effects. A comparison of serum 1 with serums 4-5 and serum ⑧ shows that the mass fractions of each component in the whitening composition containing PDRN and SOD enzymes are within the range defined in this invention, and its whitening effect is better. A comparison of serum 1 with serums ①-⑦ shows that there is a significant synergistic effect among the components in the whitening composition containing PDRN and SOD enzymes of this invention.

[0146] The embodiments described above are some, but not all, of the embodiments of this application. The detailed description of the embodiments of this application is not intended to limit the scope of the claimed application, but merely to illustrate selected embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of this application without inventive effort are within the scope of protection of this application.

Claims

1. A whitening composition containing PDRN and SOD enzyme, characterized in that, The composition comprises the following components in parts by weight: Selaginella extract: 2-4 parts; Mulberry root extract: 1-3 parts; Oenanthera extract: 8-10 parts; Nucleotide-protein complex: 0.5-1.5 parts; The nucleotide-protein complex includes PDRN and SOD enzyme; The average molecular weight of the PDRN is 50-850 kDa; the SOD enzyme activity is 50,000-200,000 U / g. The mass ratio of PDRN to SOD enzyme in the nucleotide protein complex is 1:0.6-1.

3.

2. The application of the whitening composition containing PDRN and SOD enzyme as described in claim 1 in the preparation of cosmetics with whitening effects.

3. The application as described in claim 2, characterized in that, The dosage form of the whitening cosmetic includes any one of face cream, lotion, and serum.

4. A whitening serum, characterized in that, The serum comprises 0.1-5 wt% of the whitening composition containing PDRN and SOD enzyme as described in claim 1.

5. The essence as described in claim 4, characterized in that, The serum also includes moisturizers, preservatives, thickeners, pH adjusters, and deionized water.

6. The essence as described in claim 5, characterized in that, The moisturizer is at least one of sodium hyaluronate, glycerin, and squalane.

7. The essence as described in claim 5, characterized in that, The preservative is at least one of p-hydroxyacetophenone, ethylhexylglycerin, and octyl glycol.

8. The essence as described in claim 5, characterized in that, The thickener is at least one of xanthan gum, hydroxyethyl cellulose, ammonium acryloyl dimethyl taurate / VP copolymer, and sodium polyacryloyl dimethyl taurate; the pH adjuster is tromethamine.

Images